Company / EPS (Diluted)
Matinas BioPharma Holdings, Inc. EPS (Diluted) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.28
FY2024
5-year range
-$5.28 / -$0.10
FY2020-FY2024
Trend
-5180.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed -5180% YoY in FY2024, a notable deviation from the 8-year average annual change of -643%.
Based on SEC 10-K filings.
-5.28 in FY2024.
Declined from $-0.12 to $-5.28 over the past 3 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, eps (diluted) decreased 5180.0% year-over-year.
- Peak eps (diluted) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$5.28 | -5180.0% |
| FY2023 | -$0.10 | - |
| FY2022 | - | - |
| FY2021 | -$0.12 | +7.7% |
| FY2020 | -$0.13 | +13.3% |
| FY2019 | -$0.15 | +58.3% |
| FY2018 | -$0.36 | -100.0% |
| FY2017 | -$0.18 | +0.0% |
| FY2016 | -$0.18 | +43.8% |
| FY2015 | -$0.32 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026